Aim

To evaluate the safety and efficacy of the administration of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the short term to the same patients in Barcelona Clinical Liver Cancer (BCLC) stages 0–B1.

Methods

From April 2014 to June 2019, we retrospectively reviewed BCLC stage 0–B1 patients with fresh hepatocellular carcinoma (HCC) lesions that were repeatedly treated by RFA (control group, n = 72), and by RFA and subsequent SBRT (case group, n = 26). Propensity score matching (PSM) was performed to reduce the selection bias between two groups. Recurrence, survival, Child–Pugh scores and short-term side effects (fever, bleeding, skin change, abdominal pain and fatigue) were recorded and analyzed.

Results

After PSM, 21 patients remained in each group. Seventeen and 20 patients in the case and control groups experienced recurrence. For these patients, the median times to progression and follow-up were 10.7 and 35.8 months, respectively. After PSM, the 1-year progression-free survival rate in case and control groups were 66.7% and 52.4%, respectively (P = 0.313). The inter-group overall survival (OS) was comparable (3 and 5-year OS rates in case groups were 87.3% and 74.8%, while rates in control groups were 73.7% and 46.3%, respectively; P = 0.090). The short-term side effects were mild, and the incidence showed no inter-group difference. The 1-year rates of the Child–Pugh score deterioration of ≥2 in case and control groups were 23.8% and 33.3% (P > 0.05), respectively.

Conclusion

The short-term administration of RFA and SBRT to the same BCLC stage 0–B1 patients may be feasible and effective because of their good prognosis and safety.

中文翻译：

---

安全性和有效性研究：射频消融和立体定向身体放射疗法在巴塞罗那临床肝癌0–B1期肝细胞癌中的短期应用

目标

评估短期内对巴塞罗那临床肝癌（BCLC）0至B1期患者的射频消融（RFA）和立体定向身体放疗（SBRT）的安全性和有效性。

方法

2014年4月至2019年6月，我们回顾性分析了经LCA（对照组，n = 72），RFA和随后的SBRT（病例组，n）反复治疗的BCLC 0–B1期新鲜肝细胞癌（HCC）病变患者= 26）。进行倾向得分匹配（PSM）以减少两组之间的选择偏差。记录并分析复发，生存率，Child-Pugh评分和短期副作用（发烧，出血，皮肤变化，腹痛和疲劳）。

结果

PSM后，每组还剩下21名患者。病例组和对照组分别有17例和20例复发。对于这些患者，进展和随访的中位时间分别为10.7和35.8个月。PSM后，病例组和对照组的1年无进展生存率分别为66.7％和52.4％（P = 0.313）。组间总生存率（OS）相当（病例组的3年和5年OS率分别为87.3％和74.8％，而对照组的分别为73.7％和46.3％；P = 0.090）。短期副作用轻微，发病率无组间差异。病例组和对照组的Child-Pugh评分的1年恶化率≥2，分别为23.8％和33.3％（P > 0.05）。

结论

由于预后和安全性良好，对同一BCLC 0–B1期患者短期应用RFA和SBRT可能是可行和有效的。